Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

FortuneRock Raises $24 Million for Protein Drug Development

publication date: Oct 29, 2014
FortuneRock (China) of Beijing completed a $24 million funding that it will use to advance its portfolio of novel protein drugs. Of the total, $20 million is earmarked for drug development and building a GMP manufacturing facility in Tianjin, which will be spun off into a separate company. The remaining $4 million will underwrite general corporate purposes, including a planned IPO. FortuneRock uses its technology platform to develop novel patent-protected, gene-based recombinant protein drugs that have substantial markets. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital